Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06323824 · ClinicalTrials.gov registry record · Phase 4
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
A Phase 4 study of Opioid Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
- 6
- Study locations
NCT06323824 is a Phase 4 study of Opioid Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 600 participants, below the 4,654-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06323824, a Phase 4 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.
Conditions Studied
Interventions
- DRUG Methadone
- DRUG Buprenorphine (BUP)
Study Locations (6)
California
- Highland Hospital Bridge Clinic at Alameda Health System - Oakland
- Outpatient Buprenorphine Induction Clinic, University of California, San Francisco - San Francisco
Colorado
- Rapid Start Clinic, Kaiser Permanente Colorado - Denver
Massachusetts
- Officed Based Addiction Treatment Program, Boston Medical Center - Boston
Minnesota
- Hennepin Healthcare Addiction Medicine - Minneapolis
West Virginia
- Marshall University Division of Addiction Sciences P.R.O.A.C.T - Huntington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2029-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06323824
The ClinicalTrials.gov registry entry for NCT06323824 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,654-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (87% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Methadone is the first listed.
NCT06323824 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06323824 about?
NCT06323824 is a clinical study titled "Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.". The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based meth...
What is the current status of trial NCT06323824?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2024-06-04. Estimated completion is 2029-05.
What conditions does trial NCT06323824 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06323824?
The interventions under investigation include: Methadone (DRUG), Buprenorphine (BUP) (DRUG).
Who is sponsoring clinical trial NCT06323824?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06323824 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Minnesota, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
RECRUITING · Phase 4
-
Assessing Optimal XRB Initiation Points in Jail
RECRUITING · Phase 4
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.